Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
复制标题
预处理强度对费城染色体阳性急性淋巴细胞白血病同种异体干细胞移植的影响
DOI：
10.1007/s12185-015-1883-0
复制
发表时间：
2015
影响因子：
2.1
通讯作者：
K. Akashi
中科院分区：
文献类型：
--
作者：
Shuichiro Takashima;T. Miyamoto;T. Kamimura;G. Yoshimoto;S. Yoshida;H. Henzan;K. Takase;Koji Kato;Yoshikiyo Ito;Y. Ohno;K. Nagafuji;T. Eto;T. Teshima;K. Akashi
我们回顾性分析了2001年至2012年期间在完全缓解（CR）时接受首次异基因干细胞移植（allo-SCT）的费城染色体阳性急性淋巴细胞白血病（Ph+ALL）患者的结局，其中清髓性预处理（MAC，n = 31）或低强度预处理（RIC，n = 15）。所有患者在allo-SCT前均接受过以酪氨酸激酶抑制剂（TKI）为基础的化疗。MAC组和RIC组的2年总生存率（OS）（57 vs 63%，p = 0.53）、无白血病生存率（50 vs 65%，p = 0.29）和非复发死亡率（39 vs 35%，p = 0.62）相似。无论预处理强度如何，allo-SCT前通过敏感聚合酶链反应评估的微小残留病（MRD）状态均不影响OS率（77 vs 54%，p = 0.28）和无白血病生存率（69 vs 51%，p = 0.48）。我们的数据表明，对于TKI联合化疗维持血液学CR的Ph+ALL患者，RIC方案可能代表了足够强度的治疗性移植前预处理。
We retrospectively analyzed the outcomes of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who underwent first allogeneic stem cell transplantation (allo-SCT) at complete remission (CR) with myeloablative conditioning (MAC, n = 31) or reduced-intensity conditioning (RIC, n = 15) between 2001 and 2012. All the patients had received tyrosine kinase inhibitor (TKI)-based chemotherapy prior to allo-SCT. Overall survival (OS) rates (57 vs 63 %, p = 0.53), leukemia-free survival rates (50 vs 65 %, p = 0.29), and non-relapse mortality rates (39 vs 35 %, p = 0.62) at 2 years were similar between the MAC and RIC groups. The minimal residual disease (MRD) status evaluated by sensitive polymerase chain reaction prior to allo-SCT did not influence the OS rate (77 vs 54 %, p = 0.28) and leukemia-free survival rate (69 vs 51 %, p = 0.48), irrespective of the conditioning intensity. Our data suggest that the RIC regimen may represent a sufficient intensity of therapeutic pre-transplant conditioning for patients with Ph+ALL who have maintained a hematological CR with TKI-combined chemotherapy.
登录
查看更多内容
影响因子：
20.3
作者：
Thomas, DA;Faderl, S;Kantarjian, H
通讯作者：
Kantarjian, H
影响因子：
20.3
作者：
LARSON, RA;DODGE, RK;SCHIFFER, CA
通讯作者：
SCHIFFER, CA
影响因子：
20.3
作者：
Ravandi, Farhad;Jorgensen, Jeffrey L.;Kantarjian, Hagop M.
通讯作者：
Kantarjian, Hagop M.
影响因子：
20.3
作者：
Fielding, Adele K.;Rowe, Jacob M.;Goldstone, Anthony H.
通讯作者：
Goldstone, Anthony H.